Chimeric Therapeutics (ASX:CHM) Research & Development: A$6.40 Mil (TTM As of Dec. 2025)


What is Chimeric Therapeutics Research & Development?

Chimeric Therapeutics ASX:CHM +1.47% Research & Development is A$6.40 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chimeric Therapeutics's Research & Development for the six months ended in Dec. 2025 was A$0.80 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.40 Mil.

Chimeric Therapeutics  (ASX:CHM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chimeric Therapeutics Research & Development Related Terms

Chimeric Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Research & Development Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
3.78 5.17 13.48 9.19 9.76

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.34 4.85 4.16 5.60 0.80

Chimeric Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$6.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$6.40 Mil mean?
Chimeric Therapeutics (ASX:CHM) has a Research & Development of A$6.40 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Research & Development too high?
Chimeric Therapeutics' current Research & Development is A$6.40 Mil.
How does Chimeric Therapeutics' Research & Development compare to VRTX and REGN?
Chimeric Therapeutics' Research & Development of A$6.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Research & Development is A$6.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current Research & Development of A$6.40 Mil. The current Research & Development is A$6.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current Research & Development is A$6.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.